• About us
• Contact

Advertisement

Organisation › Details

Qiagen N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. *

 

	Start	1997-01-01 existent
	Group	Qiagen (Group)
	Industry	sample preparation (technology)
	Industry 2	molecular diagnostics
	Person	Bernard, Thierry (Qiagen 201502– SVP Molecular Dx business area before bioMérieux Corp VP Commcercial Operations)
	Region	Venlo
	Country	Netherlands
	Street	50 Spoorstraat
	City	5911 KJ Venlo
		Address record changed: 2020-12-02
Basic data	Employees	G: 5,001 to 10,000 (2022-12-31)
	Currency	USD
	Annual sales	2,141,518,000 (net sales, consolidated (2022) 2022-12-31)
	Profit	423,211,000 (2022-12-31)
	Cash	730,669,000 (2022-12-31)
		* Document for »About Section«:
		Record changed: 2024-09-22

Advertisement

More documents for Qiagen (Group)

• [1] Evonetix Ltd.. (6/13/22). "Press Release: Colin McCracken Joins Evonetix as Chief Executive Officer"....
• [2] Qiagen N.V.. (8/13/20). "Press Release: Qiagen to Continue Successful Growth Strategy Focused on Execution and Greater Value Creation after Voluntary Public Takeover Offer Falls Short". Venlo....
• [3] Thermo Fisher Scientific Inc.. (8/4/20). "Press Release: Thermo Fisher Scientific Confirms Offer to Acquire Qiagen Shares Expires on August 10". Waltham, MA....
• [4] Qiagen N.V.. (7/16/20). "Press Release: Thermo Fisher Scientific and Qiagen N.V. Agree on Amended Terms to Acquisition Agreement". Waltham, MA & Venlo....
• [5] Qiagen N.V.. (3/24/20). "Press Release: Qiagen Names Thierry Bernard as Chief Executive Officer". Venlo, Hilden & Germantown, MD....
• [6] Proteomedix AG. (1/10/20). "Press Release: Proteomedix Appoints Helge Lubenow as New CEO". Zürich-Schlieren....
• [7] Qiagen N.V.. (11/15/19). "Press Release: Qiagen Receives Several Conditional, Non-binding Indications of Interest, Enters into Discussions to Explore Potential Strategic Alternatives". Venlo....
• [8] Tecan Group Ltd.. (3/8/19). "Press Release: Qiagen and Tecan Announce Collaboration to Streamline Preanalytical Processing of QuantiFERON-TB Gold Plus". Männedorf, Germantown, MD & Hilden....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.